<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182854</url>
  </required_header>
  <id_info>
    <org_study_id>YN2017QN15</org_study_id>
    <nct_id>NCT04182854</nct_id>
  </id_info>
  <brief_title>Use of Diuretics in Maintenance Hemodialysis Patients Undergoing Bioimpedance-guided Fluid Management</brief_title>
  <official_title>Use of Diuretics in Maintenance Hemodialysis Patients With Residual Renal Function Undergoing Bioimpedance-guided Fluid Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background.The objective of the present study is to verify whether using diuretics will
      improve either blood pressure or fluid overload in maintenance hemodialysis patients with
      residual diuresis kidney function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods.46 maintenance hemodialysis patients will be given three stages of diuretic
      intervention: 100mg furosemide every day for 1 month, 200mg furosemide every day for 1 month,
      and 100mg furosemide combined with 25mg hydrochlorothiazide every day for 1 month. The
      24-hour urine volume, 24-hour urine sodium, 24-hour urine potassium, blood pressure,
      OH(overhydration) and dry weight will be collected. OH will be measured by bioelectrical
      impedance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urine volume increasing after diuretic use in maintenance hemodialysis patients with residual renal function</measure>
    <time_frame>up to 16 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Diuretic Abuse</condition>
  <arm_group>
    <arm_group_label>diuretics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemid hydrochlorothiazide</intervention_name>
    <description>furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;</description>
    <arm_group_label>diuretics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  maintenance hemodialysis patient

          -  unrine volume more than 100ml.

        Exclusion Criteria:

          -  myocardial infarction;

          -  unrine volume less than 100ml.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yunfei Ding, Master</last_name>
    <phone>13521586952</phone>
    <email>dingyunfei@pkuih.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zhoucang Zhang, Master</last_name>
    <phone>17710230157</phone>
    <email>zhangzhoucang@pkuih.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University internation Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102206</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongliang Zhang, Doctor</last_name>
      <phone>86-010-69006549</phone>
      <email>zhangdongliang@pkuih.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Zhoucang Zhang, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yunfei Ding, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University International Hospital</investigator_affiliation>
    <investigator_full_name>Dongliang Zhang, MD</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>furosemide</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <keyword>residual renal function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

